Adenylosuccinate Lyase (ADSL) Deficiency

Adenylosuccinate lyase deficiency is a very rare, inherited metabolic brain disorder. It happens when changes (mutations) in the ADSL gene reduce the work of an enzyme that is needed to make and recycle purines—the building blocks for DNA, RNA, and energy molecules like ATP. When the enzyme is weak, two “succinyl-purines” build up in body fluids: SAICAr and S-Ado. These chemicals are linked to brain dysfunction. Children usually have developmental delay, seizures, low muscle tone, and often autistic features. Doctors confirm the diagnosis by finding the succinyl-purines in urine/CSF and by genetic testing for ADSL variants. There is no proven cure yet; care is supportive and seizure-focused. MedlinePlusPMCPubMed

Adenylosuccinate lyase (ADSL) deficiency is a genetic brain and body chemistry disorder. ADSL is an enzyme your cells need to build purines, which are tiny building blocks used for energy (ATP) and signals (AMP) in the brain and the rest of the body. When the ADSL enzyme does not work well (because of changes in the ADSL gene from both parents), two chemicals—SAICAr and S-Ado—build up in the blood, urine, and spinal fluid. This chemical build-up is linked with developmental delay, speech problems, seizures, low or high muscle tone, and autistic-like behaviors. The illness has a wide range of severity, from very severe in babies to milder forms in children or adults. There is no single laboratory cure today, but early diagnosis and supportive treatment can improve comfort, safety, and developmental skills. MedlinePlusPubMedNature

Other names

This condition is also called ADSL deficiency, ADSLD, adenylosuccinase deficiency, or adenylosuccinate lyase deficiency. In medical databases you may also see identifiers like Orphanet 46, OMIM 103050, MedGen C0268126, or MONDO:0007068. All these labels refer to the same inborn error of purine metabolism caused by pathogenic variants in the ADSL gene. National Organization for Rare DisordersNCBI

Types

Doctors group ADSL deficiency by how severe and how early symptoms appear. Think of it as a spectrum. The three core forms are:
1) Fatal neonatal form. Signs show before or right after birth: severe brain dysfunction, little or no spontaneous movement, feeding and breathing problems, and uncontrollable seizures. Sadly, survival is usually only weeks. MedlinePlus
2) Type I (severe infantile form). Symptoms begin in the first months of life. Children have severe psychomotor delay, microcephaly, early seizures, and mainly neurological problems. National Organization for Rare DisordersPMC
3) Type II (mild-to-moderate form). Development is delayed but less severe. Seizures may start later or be absent; autistic traits and language delay are common; some children walk and communicate better than in type I. Long-term follow-up shows variable but sometimes stable courses. National Organization for Rare DisordersPMC

A helpful lab clue about severity is the S-Ado/SAICAr ratio in body fluids: the lower the ratio, the worse the clinical picture (≈ <1 in neonatal fatal, ~1 in type I, ≥ 2 in type II). BioMed Central

---

Causes

In simple terms, “cause” here means the root genetic defect and the main biological reasons the brain is affected.

1. Biallelic ADSL mutations (autosomal recessive). A child inherits one faulty copy from each parent; this is the fundamental cause. BioMed Central

2. Loss-of-function changes. Many are missense variants that reduce enzyme activity; others are nonsense, frameshift, or splice variants. PMC

3. Defective enzyme tetramer assembly. ADSL normally works as a homotetramer; interface mutations weaken stability and function. PMC

4. Active-site disruption. Variants near the catalytic entrance lower turnover of the natural substrates. PMC

5. Purinosome disturbance. ADSL helps form the multi-enzyme purinosome; defects reduce pathway flux. MedlinePlusPubMed

6. Blocked de novo purine synthesis. Two ADSL-catalyzed steps slow down, stressing nucleotide balance in neurons. MedlinePlus

7. Blocked purine nucleotide cycle. The cycle that recycles AMP is impaired, which may burden energy-hungry brain cells. ScienceDirect

8. Build-up of SAICAr. This succinyl-purine accumulates and is thought to be neurotoxic. PMC

9. Build-up of S-Ado. Also accumulates; the S-Ado/SAICAr ratio tracks clinical severity. BioMed Central

10. Impaired myelination signaling. Abnormal purine balance is associated with hypomyelination on MRI. PMC

11. Abnormal white-matter development. MRI often shows delayed myelination and volume loss. Radiopaedia

12. Synaptic/neuronal dysfunction. Purines influence synapse formation and neurotransmission; imbalance contributes to seizures and autism-like traits (inference from pathway biology). MedlinePlus

13. Genotype–phenotype effects. Some variants correlate with milder or severe forms. BioMed Central

14. Founder effects. Clusters in the Netherlands and Belgium reflect historical variant enrichment. MedlinePlus

15. Compound heterozygosity. Having two different damaging variants can still cause the disease. SAGE Journals

16. Enzyme thermolability. Certain mutants are less stable, lowering activity in living cells (shown in biochemical characterizations). PMC

17. Reduced AMP production via S-AMP step. One blocked reaction is conversion of adenylosuccinate to AMP. MedlinePlus

18. Reduced AICAR production via SAICAR step. The other blocked reaction is conversion of SAICAR to AICAR. MedlinePlus

19. Ineffective compensation by salvage pathway. Salvage helps, but not enough to prevent brain symptoms (consensus in reviews). PubMed

20. Consanguinity increases risk. Parents related by blood have a higher chance to share the same rare variant. (General Mendelian principle; noted across case series.) BioMed Central

---

Symptoms

1. Global developmental delay. Children sit, walk, and talk later than expected; learning is slow. PubMed

2. Seizures. Can start in early infancy; may be hard to control and take many forms (spasms, focal, generalized). PubMed

3. Hypotonia (low muscle tone). Babies feel “floppy,” which affects feeding and posture. PubMed

4. Microcephaly. Head size is small for age, especially in severe forms. MedlinePlus

5. Autistic features. Poor eye contact, repetitive behaviors, and social-communication difficulties are frequent. National Organization for Rare Disorders

6. Intellectual disability. Ranges from severe to mild, tracking with clinical form. BioMed Central

7. Feeding difficulty and failure to thrive. Poor suck, reflux, or slow weight gain can occur, especially in severe forms. MedlinePlus

8. Irritability or sleep disturbance. Non-specific but often reported in infants with neurological distress. PubMed

9. Abnormal movements or ataxia. Unsteady gait and coordination problems may appear in milder cases. Wikipedia

10. Spasticity or hyperreflexia. Some children develop increased tone in the limbs over time. Wikipedia

11. Language delay (expressive > receptive). Understanding can be better than speaking in type II. Wikipedia

12. Visual/auditory contact fluctuations. Intermittent attention or responsiveness may be noted. Wikipedia

13. Breathing problems in newborn period. A feature of the fatal neonatal form. MedlinePlus

14. Encephalopathy. General brain dysfunction with lethargy and poor responsiveness in severe forms. MedlinePlus

15. Behavioral challenges. Agitation, tantrums, or self-injury can occur with autistic traits. Wikipedia

---

Diagnostic tests

A) Physical examination

1. Growth and head size check. Measures height/weight and occipital-frontal circumference to detect microcephaly or failure to thrive—common in severe forms. MedlinePlus

2. Neurological tone and reflexes. Looks for hypotonia in infancy and evolving spasticity/hyperreflexia later; helps stage severity. PubMed

3. Developmental milestones review. Documents delays in motor and language skills; guides therapy planning. PubMed

4. Behavioral and social interaction screening. Notes autistic features (eye contact, stereotypies, social reciprocity). National Organization for Rare Disorders

5. Feeding and respiration assessment (neonates). Identifies early feeding difficulty and breathing problems seen in the fatal neonatal form. MedlinePlus

B) Manual / bedside tests

6. Standardized developmental testing (e.g., Bayley scales). A hands-on assessment of cognition, language, and motor skills to quantify delay. (General pediatric neurodevelopment practice.)

7. Autism screening (e.g., M-CHAT). A simple, caregiver-guided tool to flag social-communication risk for early intervention. (General developmental screening practice.)

8. Bedside cranial nerve exam (eye tracking, facial movements, swallow). Checks basic brainstem and cortical functions affected in encephalopathy. (Neurology exam standards.)

9. Gait and coordination exam. Observes stance, balance, and finger-to-nose to pick up ataxia in milder forms. Wikipedia

C) Laboratory & pathological tests

10. Urine succinyl-purines by HPLC/LC-MS/MS. The key screening test. SAICAr and S-Ado are high in urine; this is more sensitive than plasma. PMC

11. CSF succinyl-purines. Confirms metabolite accumulation; also allows S-Ado/SAICAr ratio, which correlates with severity. BioMed Central

12. Plasma succinyl-purines. Helpful when urine/CSF are unavailable, but less sensitive; a normal plasma test does not exclude the disease. PMC

13. ADSL gene testing (sequencing/exome). Confirms biallelic pathogenic variants; also used when metabolites are borderline. BioMed Central

14. Enzyme activity in fibroblasts/lymphocytes (specialized). Measures residual ADSL activity to support uncertain genetic results. (Specialty lab practice discussed in reviews.) ScienceDirect

15. Broader metabolic screen (organic acids, acylcarnitines). Usually non-specific, but helps rule out mimicking metabolic disorders. (Diagnostic workflow in metabolic clinics.)

16. Genetic panels for epileptic encephalopathy or leukodystrophy. Useful when presentation is non-specific; ADSL is included in many panels. (Contemporary genetics practice.)

D) Electrodiagnostic tests

17. Electroencephalogram (EEG). Often shows multifocal spikes; in severe infants may show hypsarrhythmia or burst-suppression patterns during refractory seizures. ResearchGate

18. Evoked potentials (as needed). Visual or auditory evoked responses may be used to profile conduction in complex cases; not specific but can complement MRI and exam. (General neurophysiology use.)

E) Imaging tests

19. Brain MRI. Common findings: delayed myelination / hypomyelination, ventriculomegaly, white-matter signal changes, thinning of the corpus callosum, and cerebral/cerebellar volume loss. These support the diagnosis but are not unique to ADSL deficiency. RadiopaediaPMC

20. Follow-up MRI. Tracks progression or stability over time, especially in type II; helps guide therapies and expectations. (Longitudinal case reports describe variable courses.) PMC

Non-pharmacological treatments

Evidence reality check: These approaches improve function, comfort, safety, learning, and family quality of life. They do not correct the enzyme defect. Always build a plan with a pediatric neurologist, metabolic specialist, dietitian, therapists, and the school team. Orpha

Physiotherapy / Movement / Daily Function

1. Neurodevelopmental physical therapy
   Purpose: Improve head control, sitting, standing, walking.
   Mechanism: Repeated task-specific practice builds neural pathways and muscle patterns.
   Benefits: Better mobility, fewer contractures, safer transfers. BioMed Central

2. Occupational therapy (fine-motor & self-care)
   Purpose: Hand use, dressing, feeding, play.
   Mechanism: Motor learning with graded tasks and adaptive tools.
   Benefits: Independence and reduced caregiver burden. BioMed Central

3. Speech-language therapy
   Purpose: Language, articulation, and swallowing skills.
   Mechanism: Structured drills; oral-motor practice; augmentative supports.
   Benefits: Clearer communication; safer eating. BioMed Central

4. Augmentative & Alternative Communication (AAC)
   Purpose: Provide a voice when speech is limited.
   Mechanism: Picture boards or speech-generating devices.
   Benefits: Reduces frustration; improves learning. BioMed Central

5. Feeding therapy
   Purpose: Safer swallowing and better nutrition.
   Mechanism: Positioning, texture modification, pacing.
   Benefits: Less aspiration, better growth. BioMed Central

6. Sensory integration strategies
   Purpose: Calm over- or under-responsive sensory systems.
   Mechanism: Controlled sensory input (vestibular, proprioceptive).
   Benefits: Improved attention and behavior. Nature

7. Posture and orthotics (AFOs, seating)
   Purpose: Prevent deformity and improve stance.
   Mechanism: External support for weak or spastic muscles.
   Benefits: Safer walking and sitting. BioMed Central

8. Contracture prevention program
   Purpose: Maintain joint range.
   Mechanism: Stretching, splints, positioning.
   Benefits: Less pain; easier care. BioMed Central

9. Gait training & mobility aids
   Purpose: Efficient movement.
   Mechanism: Body-weight support, walkers, or wheelchairs.
   Benefits: Energy conservation and participation. BioMed Central

10. Seizure safety training
    Purpose: Reduce injury during events.
    Mechanism: Environmental adaptations; caregiver drills.
    Benefits: Fewer accidents; calmer response. Wiley Online Library

11. Sleep hygiene program
    Purpose: Consolidate sleep to reduce seizures and irritability.
    Mechanism: Consistent schedules, light control, calming routines.
    Benefits: Better daytime function and seizure control. Wiley Online Library

12. Respiratory physiotherapy (if weak cough)
    Purpose: Keep lungs clear.
    Mechanism: Positioning, assisted cough, suction plans.
    Benefits: Fewer chest infections. BioMed Central

13. Early intervention/therapy intensity
    Purpose: Maximize brain plasticity.
    Mechanism: Frequent, play-based, family-centered sessions.
    Benefits: Better skill acquisition long-term. BioMed Central

14. Community-based rehabilitation & respite
    Purpose: Reduce caregiver burnout, maintain therapy at home.
    Mechanism: Trained aides; home programs.
    Benefits: Sustainable care, improved quality of life. BioMed Central

15. Nutritional therapy (team-supervised; see diet section)
    Purpose: Support growth/energy, consider ketogenic diet for seizures if appropriate.
    Mechanism: Calorie/protein optimization; special diets under medical monitoring.
    Benefits: Better weight gain; sometimes fewer seizures. BioMed Central

Mind-Body, “Gene”, and Educational Therapies

16. Caregiver education & emergency plans – know seizure first-aid, medication schedules, and when to seek help. Benefit: Faster, safer responses. Wiley Online Library

17. Behavior therapy (e.g., ABA-informed strategies) – builds communication and reduces harmful behaviors. Benefit: Better participation and learning. Nature

18. Individualized Education Program (IEP) – tailored school supports (speech, OT, PT, AAC). Benefit: Appropriate goals and accommodations. BioMed Central

19. Parent training in AAC and behavior supports – keeps therapy consistent at home. Benefit: Faster progress. BioMed Central

20. Psychological support for family – coping skills; reduces stress that can worsen child behaviors. Benefit: Healthier family system. BioMed Central

21. Sleep behavior therapy – structured routines and stimulus control. Benefit: Fewer night wakings; better seizure control. Wiley Online Library

22. Clinical-trial readiness & genetic counseling – understand inheritance, risks to future pregnancies, and research options. Benefit: Informed choices; potential access to new therapies. BioMed Central

23. Ethical, supervised trials of special diets (e.g., ketogenic for epilepsy) – only with specialists. Benefit: May help seizures in selected cases. BioMed Central

24. Future-looking gene therapy research discussions – ADSL gene replacement is being explored in labs/fundraising initiatives; not yet a treatment. Benefit: Awareness of evolving science. UAB Barcelona

25. Peer-support and rare-disease networks – practical tips and advocacy. Benefit: Reduced isolation; better resource navigation. National Organization for Rare Disorders

---

Pharmacologic treatments

There is no approved disease-specific drug for ADSL deficiency. Medications below are used to treat seizures, spasticity, sleep/behavior, reflux/feeding, etc. Exact dosing must be individualized by the child’s clinician; the choices and combinations depend on seizure type, age, comorbidities, and interactions. OrphaPMC

1. Levetiracetam (ASM; broad-spectrum) – Purpose: reduce focal/generalized seizures. Mechanism: SV2A modulation to stabilize synaptic release. Side effects: irritability, somnolence.

2. Valproate (ASM; broad-spectrum) – useful for generalized epilepsies; watch liver/platelets and avoid in certain mitochondrial disorders and pregnancy. Side effects: weight gain, tremor, hepatotoxicity risk.

3. Clobazam (benzodiazepine ASM) – adjunct for refractory seizures. Side effects: sedation, tolerance.

4. Topiramate (ASM) – for focal/generalized seizures; may curb appetite. Side effects: cognitive slowing, kidney stones.

5. Oxcarbazepine (ASM) – for focal seizures. Side effects: hyponatremia, dizziness.

6. Lamotrigine (ASM) – broad utility; slow titration to reduce rash risk.

7. Vigabatrin (ASM) – for infantile spasms (specialist use; retinal toxicity monitoring).

8. Phenobarbital (ASM) – sometimes used in neonates; sedation/cognitive side effects.

9. Rescue benzodiazepines (diazepam/nasal midazolam) – for prolonged seizures or clusters; caregiver-administered rescue plans reduce ER visits.

10. Baclofen (oral) – reduces spasticity; may cause drowsiness/weakness.

11. Tizanidine – alternative antispasticity agent; monitor liver function.

12. Melatonin – supports sleep initiation/maintenance; improves family rest and seizure threshold in some.

13. Proton-pump inhibitor or H2-blocker – treats reflux that worsens feeding and sleep.

14. Stool softeners/fiber agents – address constipation from low tone and meds.

15. Vitamin D and calcium (if needed) – bone health support in non-ambulatory children or those on enzyme-inducing ASMs.

Rationale across items: Reducing seizure burden and treating comorbid symptoms improves development and quality of life even when the underlying enzyme defect remains. (Drug selection follows standard pediatric neurology practice patterns for epilepsy and tone disorders; consult your neurologist for individualized regimens.)

---

Dietary molecular supplements

Important: Evidence is limited (mostly case reports or small series). None of these supplements has proven disease-modifying benefit for ADSL deficiency. Any trial should be ethics-approved, monitored, and stopped if no clear benefit. PMCBioMed Central

1. D-ribose – may support ATP production and purine salvage; isolated reports of improved coordination or seizure control; evidence remains weak. Functional mechanism: energy substrate. PMCScienceDirect

2. Uridine – proposed to balance nucleotide pools; very limited data in ADSL; sometimes paired with D-ribose in reports. PMC

3. S-adenosyl-L-methionine (SAMe) – studied as a potential treatment; no convincing clinical or biochemical improvement shown. Mechanism: methyl donor. PubMedBioMed Central

4. Creatine monohydrate – general brain-energy support concept used in other neurometabolic disorders; no ADSL-specific proof.

5. Omega-3 fatty acids – may aid neurodevelopment and behavior in general pediatric populations; ADSL-specific data lacking.

6. Carnitine – if documented deficiency or poor intake; supports fatty-acid transport; no ADSL-specific evidence.

7. Multivitamin with folate – overall nutrition support; does not fix purine synthesis defect.

8. Probiotics (feeding tolerance) – may help reflux/constipation symptoms; no disease-specific effect.

9. Electrolyte-balanced oral rehydration solutions – during illness to prevent dehydration-triggered seizures.

10. Ketogenic diet (dietary therapy, not a pill) – specialist-supervised high-fat, low-carb regimen that can reduce refractory seizures in some cases; effectiveness varies; needs strict monitoring. BioMed Central

(Deliberately not listing fixed “dosages” here because dosing is individualized and, for most items, not evidence-based for ADSL; using exact numbers without a treating team is unsafe.)

---

Immunity-booster / regenerative / stem-cell” drug concepts

1. AAV-based ADSL gene therapy (preclinical/advocacy stage) – replace functional ADSL gene to restore enzyme activity; no approved human therapy yet. UAB Barcelona

2. mRNA therapy (theoretical) – deliver ADSL mRNA to cells to produce enzyme transiently; currently conceptual for ADSL.

3. Small-molecule chaperones – stabilize misfolded ADSL proteins to improve residual activity; early-stage idea. PubMed

4. Substrate-reduction therapy – lower SAICAr formation upstream to reduce toxicity; theoretical for ADSL. PubMed

5. Purinosome modulators – guide enzyme clustering to improve pathway efficiency; basic-science concept. PubMed

6. Cell-based therapy – stem-cell replacement to supply enzyme is speculative and not available for ADSL.

Bottom line: None of these are approved treatments; if discussed, it should be within formal research programs with proper oversight.

---

Procedures/surgeries

1. Vagus Nerve Stimulation (VNS) – implantable device for drug-resistant epilepsy; can reduce seizure frequency/intensity. Why: when multiple ASMs and diet have failed. Wiley Online Library

2. Gastrostomy tube (G-tube) – for persistent unsafe swallowing or poor weight gain despite therapy. Why: ensures safe, adequate nutrition and meds. BioMed Central

3. Intrathecal baclofen pump – for severe spasticity not controlled by oral meds. Why: improves comfort, hygiene, and care.

4. Orthopedic tendon-lengthening/bony procedures – for fixed contractures or deformities limiting care/mobility. Why: reduce pain, improve seating/walking.

5. Tracheostomy (rare) – when chronic aspiration and airway protection remain unsafe despite all measures. Why: airway safety and secretion management.

---

Prevention

1. Genetic counseling for parents and relatives; discuss carrier testing and future pregnancy options. BioMed Central

2. Early diagnosis of siblings (biomarkers/genetics) for prompt therapy services. Wiley Online Library

3. Vaccinations on schedule to reduce fever-triggered seizures and hospitalizations.

4. Seizure action plan + rescue medication at home and school. Wiley Online Library

5. Nutrition monitoring to avoid under-nutrition and dehydration. BioMed Central

6. Sleep routines to support seizure control. Wiley Online Library

7. Regular therapy intensity (PT/OT/SLP/AAC) to sustain gains. BioMed Central

8. Dental and aspiration prevention (oral care, feeding safety).

9. Infection-control habits (hand hygiene; rapid treatment of illness).

10. Environmental seizure safety (water safety, padded corners, supervision). Wiley Online Library

---

When to see doctors

• First unprovoked seizure or any change in seizure pattern (longer, more frequent, or different).

• Breathing problems, blue color, or unresponsive spells after a seizure.

• Feeding refusal, choking, or weight loss.

• Persistent vomiting, dehydration, or fever that triggers clusters.

• Sudden regression (loss of skills) or new weakness/spasticity.

• Severe sleep disruption affecting day function.

• Any trial of supplements or special diet—must be planned and supervised by the care team. Wiley Online LibraryBioMed Central

---

What to eat and what to avoid

• Eat: balanced meals with adequate calories and protein; fiber for bowel health; hydration to lower seizure triggers from dehydration. Work with a dietitian for growth goals. BioMed Central

• Consider: a ketogenic diet or modified Atkins only if the epilepsy team recommends it; it can help some children’s seizures but needs strict monitoring (lipids, kidney stones, micronutrients). BioMed Central

• Avoid: unsupervised supplement megadoses; prolonged fasting; “internet cures” that promise enzyme “restoration.”

• During illness: small, frequent fluids with electrolytes; keep medicines on schedule; follow the seizure plan.

---

Frequently asked questions

1. Is there a cure?
   Not yet. Care focuses on seizure control, nutrition, and developmental/educational therapies while research explores gene-based options. OrphaUAB Barcelona

2. How is the diagnosis confirmed?
   By finding SAICAr and S-Ado on biochemical testing and confirming ADSL gene variants by genetic testing. PubMed

3. Does the S-Ado/SAICAr ratio matter?
   A lower ratio often indicates more severe disease, though not perfectly. PubMed

4. What does MRI show?
   Often white-matter changes and other findings that help with prognosis and therapy planning. PubMed

5. Which antiseizure medicine is “best”?
   There is no single best drug; choices depend on seizure type and the child’s profile. A pediatric neurologist tailors therapy. Wiley Online Library

6. Can ketogenic diet help?
   Sometimes, for refractory seizures—only with specialist supervision. BioMed Central

7. Do D-ribose, uridine, or SAMe work?
   Evidence is weak or negative; small reports exist, but no proven benefit. Use only in research/specialist settings. PMCPubMed

8. Is this inherited?
   Yes, autosomal recessive—both parents are typically carriers. Genetic counseling is recommended. MedlinePlus

9. What is the outlook?
   It varies widely. Early-infantile forms can be severe; attenuated forms exist. Early supports improve quality of life. BioMed Central

10. Can adults have ADSL deficiency?
    Yes—milder/attenuated forms can present later. BioMed Central

11. Are stem cells a treatment?
    No approved stem-cell therapy exists for ADSL deficiency. Orpha

12. Will better sleep help?
    Yes. Good sleep can reduce seizures and improve behavior. Wiley Online Library

13. What about vaccines?
    Stay current to reduce infections and fevers that can trigger seizures.

14. Can my child go to school?
    Yes—with an IEP, therapies, AAC, and seizure plan many children attend school and make progress. BioMed Central

15. Where can I learn more or find support?
    Rare-disease groups and medical genetics clinics help families with education, services, and research opportunities. National Organization for Rare Disorders

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 08, 2025.